Urol. praxi. 2021;22(4):195-202 | DOI: 10.36290/uro.2021.032

A diabetic patient at the urological clinic

MUDr. Pavlína Pi»hová, Ph.D.
Interní klinika UK 2. LF a FN v Motole, Praha

Diabetes mellitus is a group of heterogenous disorders characterized by chronic hyperglycaemia. Diabetic patients could visit urological clinic due to urinary tract infections (including serious emphysematous pyelonephritis), functional disorders of urinary tract or malignant disorders.

Keywords: diabetes mellitus, diabetic nephropathy, urine tract infections, dysmotility of urine tract.

Received: July 15, 2021; Revised: September 19, 2021; Accepted: September 19, 2021; Prepublished online: September 19, 2021; Published: November 24, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pi»hová P. A diabetic patient at the urological clinic. Urol. praxi. 2021;22(4):195-202. doi: 10.36290/uro.2021.032.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Pelikánová T, Bartoą V. Praktická diabetologie. 6 ed. Praha: Maxdorf; 2018.
    2. https://www.uzis.cz/sites/default/files/knihovna/nzis_rep_2018_K01_A004_diabet_endokrin_2018.pdf.
    3. Za ČDS: J. ©krha, T. Pelikánová, M. Prázný, M. Kvapil, Doporučený postup péče o diabetes mellitus 2. typu. Revize ze dne: 31. 5. 2020, www.diab.cz/standardy.
    4. Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). DIABETES CARE 2018; 41: 2669-2701. Go to original source... Go to PubMed...
    5. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359: 1577-89. Go to original source... Go to PubMed...
    6. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352: 854-65.
    7. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005; 366: 1279-89. Go to original source... Go to PubMed...
    8. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016; 375: 311-22. Go to original source... Go to PubMed...
    9. Leiter LA, Bain SC, Hramiak I, Jódar E, et al. Cardiovascular risk reduction with once‑weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. Cardiovasc Diabetol 2019; 18: 73. https://doi.org/10.1186/s12933-019-0871-8. Go to original source... Go to PubMed...
    10. Zinman B, Wanner C, Lachin JM, Fitchett D, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373: 2117-2128. Go to original source... Go to PubMed...
    11. Wanner C, Inzucchi SE, Lachin JM, Fitchett D et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016;375:323-34. Go to original source... Go to PubMed...
    12. Marso S, McGuire D, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017; 377: 723-732. Go to original source... Go to PubMed...
    13. Za výbory odborných společností: Pelikánová T, Viklický O, Rychlík I, Saudek F, Kvapil M, Tesař V, Zima T, Bouček P. Česká diabetologická společnost ČLS JEP, Česká nefrologická společnost a Česká společnost klinické biochemie ČLS JEP doporučené postupy při diabetickém onemocnění ledvin https://www.diab.cz/dokumenty/standard_dmev_ledviny.pdf
    14. Kladenský J. Infekce močových cest a diabetes mellitus. Urol. praxi 2013; 14(2): 56-58.
    15. Venmans LM, Sloof M, Hak E, et al. Prediction of complicated urinary tract infections with type 2 diabetes: a questionnaire study in primary care. Eur J Epidemiol 2007; 22(1): 49-54. Go to original source... Go to PubMed...
    16. Macek, P. Komplikované infekce močových cest. Urolog. praxi, 2010; 11(6): 302-307.
    17. Raz R. Asymptomatic bacteriuria: clinical significance and management. Int J Antimicrob Agents 2003; 22(Suppl. 2): 45-47. Go to original source... Go to PubMed...
    18. Lin K, Fajardo K. Screening for asymptomatic bacteriuria in adults: evidence for the U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med 2008; 149: W20-W24. Go to original source... Go to PubMed...
    19. Meiland R, Geerlings SE, Stolk RP, Netten PM, et al. Asymptomatic bacteriuria in women with diabetes mellitus: effect on renal function after 6 years of follow-up. Arch Intern Med 2006; 166: 2222-2227. Go to original source... Go to PubMed...
    20. Renko M, Tapanainen P, Tossavainen P, Pokka T, et al. Meta-Analysis of the Significance of Asymptomatic Bacteriuria in Diabetes. Diabetes Care 2011; 34: 230-235. Go to original source... Go to PubMed...
    21. Huang JJ, Tseng CC. Emphysematous pyelonephritis: clinicoradiological classification, management, prognosis, and pathogenesis. Arch Intern Med. 2000; 160(6): 797-805. Go to original source... Go to PubMed...
    22. Roy C, Pfleger DD, Tuchmann CM, Lang HH, et al. Emphysematous pyelitis: Findings in five patients. Radiology. 2001; 218: 647-50. Go to original source... Go to PubMed...
    23. Thomas AA, Lane BR, Thomas AZ, Remer EM, Campbell SC, Shoskes DA. Emphysematous cystitis: A review of 135 cases. BJU Int. 2007; 100: 17-20. Go to original source... Go to PubMed...
    24. Coelho RF, Schneider-Monteiro ED, Mesquita JL, Mazzucchi E, et al. Renal and perinephric abscesses: Analysis of 65 consecutive cases. World J Surg. 2007; 31: 431-6. Go to original source... Go to PubMed...
    25. Norton KS, Johnson LW, Perry T, et al. Management of Fournier's gangrene: an eleven year retrospective analysis of early recognition, diagnosis, and treatment. Am Surg. 2002; 68(8): 709-713 Go to original source... Go to PubMed...
    26. Brod'ak M, Romzova M, Kosina J. Urologic surgery in diabetes. Vnitr Lek. 2008; 54(5): 457-463 Go to PubMed...
    27. Bersoff-Matcha S, Chamberlain Ch, Cao Ch, Kotepeter C, et al. Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases. Ann Intern Med 2019; 170(11): 764-769. doi: 10.7326/M19-0085. Epub 2019 May 7. Go to original source... Go to PubMed...
    28. Macek P. Fournierova gangréna. In: Zámečník L, Macek P, et al. Moderní farmakoterapie v urologii. Praha: Maxdorf; 2012: 45-48.
    29. Kawaguchi Y, Mori H, Izumi Y, Ito M. Renal Papillary Necrosis with Diabetes and Urinary Tract Infection. Intern Med. 2018; 57(22): 3343. doi: 10.2169/internalmedicine.0858-18. Epub 2018 Jul 6.PMID: 29984778. Go to original source... Go to PubMed...
    30. Jung DC, Kim SH, Jung SI, Hwang SI, Kim SH. Renal papillary necrosis: review and comparison of findings at multi-detector row CT and intravenous urography. Radiographics 2006; 26: 1827-1836. Go to original source... Go to PubMed...
    31. Tallai B, Gulistan TG, Alrayashi MN, Al Mughalles SAA, et al. A Rare Presentation of Renal Papillary Necrosis in a COVID-19-Positive Patient. Case Rep Urol. 2021 Jan 11;2021:6611861. doi: 10.1155/2021/6611861. eCollection 2021. https://pubmed.ncbi.nlm.nih.gov/33489409/ - affiliation-1. Go to original source...
    32. Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC. Time trends in reported prevalence of kidney stones in the United States: 1976- 1994. Kidney Int. 2003; 63: 1817-23. Go to original source... Go to PubMed...
    33. Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. JAMA 2005; 293: 455-62. Go to original source... Go to PubMed...
    34. Eisner BH, Porten SP, Bechis SK, Stoller ML. Diabetic kidney stone formers excrete more oxalate and have lower urine pH than nondiabetic stone formers. J. Urol. 2010; 183: 2244-2248. Go to original source... Go to PubMed...
    35. Taguchi K, Okada A, Yasui T, et al. Pioglitazone, a peroxisome proliferator activated receptor c agonist, decreases renal crystal deposition, oxidative stress and inflammation in hyperoxaluric rats. J. Urol. 2012; 188: 1002-11. Go to original source... Go to PubMed...
    36. Lestienne P, Reynier P, Chretien MF, Penisson-Besnier I et al. Oligoasthenospermia associated with multiple mitochondrial DNA rear-rangements. Mol Hum Reprod (1997) 3:811-4. doi:10.1093/molehr/3.9.811 11. Go to original source... Go to PubMed...
    37. Chan JL, Mantzoros CS. Leptin and the hypothalamic-pituitary regulation of the gonadotropin-gonadal axis. Pituitary 2001; 4: 87-92. doi:10.1023/ A:1012947113197. Go to original source... Go to PubMed...
    38. Trojan O. Diabetes mellitus a erektilní dysfunkce. Med. praxi 2011; 8(5): 226-229.
    39. ©ochman J. Poąkození ledvin kontrastními látkami. In: Teplan V et al. Akutní poąkození a selhání ledvin v klinické medicíně. Praha: Grada 2010: 303-324.
    40. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105: 2259-2264. Go to original source... Go to PubMed...
    41. Barrett BJ, Parfrey PS. Preventing nephropathy induced by contrast medium. N Engl J Med 2006; 354: 379-386. Go to original source... Go to PubMed...
    42. Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast mediaassociated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002; 162: 329-336 Go to original source... Go to PubMed...
    43. Teplan V. Kontrastová nefropatie a moľnosti její prevence. Vnitř Lék 2012; 58(7&8): 553-556 Go to PubMed...
    44. Mokrią J, Zachoval R., Záleský M., Borovička V, et al. Dysfunkce dolních močových cest u diabetických pacientů. Ces Urol 2016; 20(4): 275-284.
    45. Park J, Cho SY, Lee YJ, et al. Poor glycemic control of diabetes mellitus is associated with higher risk of prostate cancer detection in a biopsy population. PLoS One 2014; 9: e104789. Go to original source... Go to PubMed...
    46. Cai H, Xu Z, Xu T, et al. Diabetes mellitus is associated with elevated risk of mortality amongst patients with prostate cancer: a meta-analysis of 11 cohort studies. Diabetes Metab Res Rev. 2015; 31: 336-43. Go to original source... Go to PubMed...
    47. Park SM, Lim MK, Shin SA, Yun YH. Impact of prediagnosis smoking, alcohol, obesity, and insulin resistance on survival in male cancer patients: National Health Insurance Corporation Study. J Clin Oncol. 2006; 24: 5017-5024. Go to original source... Go to PubMed...
    48. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304-1305. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.